79 related articles for article (PubMed ID: 3480754)
21. Effects of dietary n-3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin-induced nephrotoxicosis in healthy male dogs.
Grauer GF; Greco DS; Behrend EN; Fettman MJ; Mani I; Getzy DM; Reinhart GA
Am J Vet Res; 1996 Jun; 57(6):948-56. PubMed ID: 8725828
[TBL] [Abstract][Full Text] [Related]
22. [The modification of the biosynthesis and effect of thromboxane A2 and prostacyclin by trapidil (Rocornal)].
Block HU; Heinroth I; Giessler C; Pönicke K; Mentz P; Zehl U; Rettkowski W; Dunemann A; Förster W
Biomed Biochim Acta; 1983; 42(2-3):283-99. PubMed ID: 6411078
[TBL] [Abstract][Full Text] [Related]
23. Hemodynamic roles of thromboxane A2 and prostaglandin E2 in glomerulonephritis.
Stork JE; Dunn MJ
J Pharmacol Exp Ther; 1985 Jun; 233(3):672-8. PubMed ID: 3859644
[TBL] [Abstract][Full Text] [Related]
24. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
[TBL] [Abstract][Full Text] [Related]
25. A fish oil diet preserves renal function in nephrotoxic serum nephritis.
Scharschmidt L; Miller M; Holthofer H; Sinha A; Schlondorff D; Gibbons N; Santiago A
J Lab Clin Med; 1990 Apr; 115(4):405-14. PubMed ID: 2324610
[TBL] [Abstract][Full Text] [Related]
26. Platelet and endothelial response with trapidil in patients with peripheral obliterative arteriopathy.
Bonfardeci G; Cimminiello C; Cantini L; Arpaia G; Aloisio M; Pozzi F
Int Angiol; 1994 Dec; 13(4):339-42. PubMed ID: 7790757
[TBL] [Abstract][Full Text] [Related]
27. Suppression of fibroblast proliferation in vitro and of myointimal hyperplasia in vivo by the triazolopyrimidine, Trapidil.
Tiell ML; Sussman II; Gordon PB; Saunders RN
Artery; 1983; 12(1):33-50. PubMed ID: 6678578
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
Zipser RD; Kronborg I; Rector W; Reynolds T; Daskalopoulos G
Gastroenterology; 1984 Dec; 87(6):1228-32. PubMed ID: 6593268
[TBL] [Abstract][Full Text] [Related]
29. A role for thromboxane in complement-mediated glomerular injury.
Cybulsky AV; Lieberthal W; Quigg RJ; Rennke HG; Salant DJ
Am J Pathol; 1987 Jul; 128(1):45-51. PubMed ID: 3111267
[TBL] [Abstract][Full Text] [Related]
30. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation.
Heinroth I; Block HU; Mest HJ
Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555
[TBL] [Abstract][Full Text] [Related]
31. Antiproliferative effect of trapidil on PDGF-associated growth of human glioma cell lines in vitro.
Tada M; Aida T; Hosokawa M; Kobayashi H; Sawamura Y; Abe H
Neurol Med Chir (Tokyo); 1991 Jun; 31(6):313-7. PubMed ID: 1724294
[TBL] [Abstract][Full Text] [Related]
32. Urinary excretion of cyclic nucleotides, creatinine prostaglandin E2 and thromboxane B2 from mice exposed to whole-body irradiation from an enhanced neutron field.
Steel LK; Rafferty MA; Wolfe WW; Egan JE; Kennedy DA; Catravas GN; Jackson WE; Dooley MA
Int J Radiat Biol Relat Stud Phys Chem Med; 1986 Oct; 50(4):695-715. PubMed ID: 3531057
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
34. Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. Concerted biosynthesis of thromboxane A2 and E-series prostaglandins.
Giembycz MA; Kroegel C; Barnes PJ
J Immunol; 1990 May; 144(9):3489-97. PubMed ID: 2158510
[TBL] [Abstract][Full Text] [Related]
35. The trapidil restenosis trial (STARC study): background, methods and clinical characteristics of the patient population.
Maresta A; Balducelli M; Cantini L; Casari A; Chioin R; Fontanelli A; Monici Preti PA; Repetto S; Raffaghello S
Clin Trials Metaanal; 1994 Apr; 29(1):31-40. PubMed ID: 10150183
[TBL] [Abstract][Full Text] [Related]
36. Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis.
Longhofer SL; Frisbie DD; Johnson HC; Culham CA; Cooley AJ; Schultz KT; Grauer GF
Am J Vet Res; 1991 Mar; 52(3):480-7. PubMed ID: 1827969
[TBL] [Abstract][Full Text] [Related]
37. Platelet-activating factor is a potent stimulus for renal prostaglandin synthesis: possible significance in unilateral ureteral obstruction.
Weisman SM; Felsen D; Vaughan ED
J Pharmacol Exp Ther; 1985 Oct; 235(1):10-5. PubMed ID: 3862805
[TBL] [Abstract][Full Text] [Related]
38. Prevention of cerebral ischemic symptoms in cerebral vasospasm with trapidil, an antagonist and selective synthesis inhibitor of thromboxane A2.
Suzuki S; Sobata E; Iwabuchi T
Neurosurgery; 1981 Dec; 9(6):679-85. PubMed ID: 7322333
[TBL] [Abstract][Full Text] [Related]
39. Renal arachidonic acid metabolism and cellular changes in the rabbit renal vein constricted kidney: inflammation as a common process in renal injury models.
Schwartz D; DeSchryver-Kecskemeti K; Needleman P
Prostaglandins; 1984 Apr; 27(4):605-13. PubMed ID: 6427853
[TBL] [Abstract][Full Text] [Related]
40. Evidence for "response to injury" hypothesis.
Ohnishi H; Yamaguchi K; Shimada S; Sato M; Funatc H; Katsuki Y; Dabasaki T; Suzuki Y; Saitoh Y; Kumagai A
Life Sci; 1982 Dec; 31(23):2595-602. PubMed ID: 7154855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
